Prices of intracellular therapies Public offering of ordinary shares – January 05, 2022

NEW YORK, January 04, 2022 (GLOBE NEWSWIRE) – Intracellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system (CNS) disorders, today announced the price of its previously announced subscribed public offering of 9,523,810 common shares at a public offering price of $ 42.00 per share. All of the shares of the offering will be sold by Intra-Cellular Therapies with the gross proceeds of the Intra-Cellular Therapies to be $ 400.0 million before the deduction of sales rebates and commissions and offering costs. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to 1,428,571 additional shares under the same terms and conditions. The closing of the offer is scheduled for January 7, 2022, subject to the satisfaction of the usual closing conditions.

JP Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets act as co-book managers for the offer. Cantor and Canaccord Genuity act as co-leaders of the offering. Needham & Company acts as co-manager of the offer.

The public offering is being made in accordance with a pre-registration statement on Form S-3 which has been previously filed with the Securities and Exchange Commission (the “SEC”) and became effective upon filing. A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at http: // www. Copies of the Final Prospectus Supplement and accompanying prospectus relating to this offering, when available, may be obtained from JP Morgan Securities LLC, attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at 1-866-803-9204, or by email at, SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by phone at 1-800-808-7525, ext. 6105, or by email, BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 or by email at dg., Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by phone at (888) 474-0200 or by email at ecm.prospectus@evercore .com, or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by phone at (877) 822-4089 or by email at

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About intracellular therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel Prize-winning research that helps us understand how therapies affect the inner workings of cells in the body. The company is using this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurological diseases.

Forward-looking statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, concerning, among other things, the completion and timing of the press release. ‘supply and the total expected gross proceeds of the offering. Intracellular therapies often use words such as “anticipates”, “believes”, “plans”, “expects”, “plans”, “the future”, “intends”, “may”, “Power”, “should”, “” could “,” estimate “,” predicted “,” potential “,” expected “,” continuing “,” direction “and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement due to various risks, uncertainties and other factors, including, but not limited to: completion of the ‘public offering and other risks and uncertainties which are described under the heading “Risk Factors” in the preliminary prospectus supplement of Intra-Cellular Therapies filed with the SEC on January 3, 2022, the most recent annual report of Intra-Cellular Therapies. ‘Intra-Cellular Therapies on Form 10-K or in subsequent filings it makes with the Securities and Exchange Commission. Due to the risks and uncertainties that intracellular therapies face, the results or events indicated by any forward-looking statement may not occur. Intra-Cellular Therapies cautions you not to place undue reliance on forward-looking statements. In addition, any forward-looking statements in this press release represent the views of Intra-Cellular Therapies only as of the date of this press release and should not be construed as representing its views at any later date. Intra-Cellular Therapies disclaims any obligation to update any forward-looking statement, except as required by applicable law.


Intracellular Therapies, Inc.
Juan Sanchez, MD
Vice-President, Corporate Communications and Investor Relations

Burns McClellan, Inc.
Lisa burns

Media inquiries:

Sara franks
W20wcg Corporate Media Relations

Main logo

About Barbara J. Ross

Check Also

Actelis Networks, Inc. Announces IPO Pricing

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Actelis Networks, Inc. ASNS (“Actelis” or the …